CoChat

Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?

Open access
Miñambres, Inka, Pérez, Antonio · 2017 · Diabetology & Metabolic Syndrome

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Abstract

Several GLP-1 receptor agonists are currently available for treatment of type 2 diabetic patients. Based on their pharmacokinetic/pharmacodynamic profile, these drugs are classified as short-acting GLP-1 receptor agonists (exenatide and lixisenatide) or long-acting GLP-1 receptor agonists (exenatide-LAR, liraglutide, albiglutide, and dulaglutide). In clinical practice, they are also classified as basal or prandial GLP-1 receptor agonists to differentiate between patients who would benefit more from one or another based on characteristics such as previous treatment and the predominance of fasting or postprandial hyperglycemia. In the present article we examine available data on the pharmacokinetic characteristics of the various GLP-1 agonists and compare their effects with respect to the main parameters used to evaluate glycemic control. The article also analyzes whether the differences between the different GLP-1 agonists justify their classification as basal or prandial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13098-017-0204-6

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 58 references

Cited by

See all 39

Metadata

Authors
Miñambres, I., & Pérez, A.
Affiliations
Universitat Autònoma de Barcelona (ES)
Corresponding author
Pérez, Antonio
Venue
Diabetology & Metabolic Syndrome
Published
2017-01-18
Volume
9
Issue
1
Pages
6-6
ISSN
1758-5996 (ISSN-L)
OpenAlex
W2576609254
Cited by
39
References
58
Citations by year
2026: 3 · 2025: 1 · 2024: 5 · 2023: 1 · 2022: 5 · 2021: 3 · 2020: 11 · 2019: 3 · 2018: 5 · 2017: 2
FWCI
0.84
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Diabetology & Metabolic Syndrome (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
Funders
  • Eli Lilly and Company
  • Sanofi
  • Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
GLP-1 receptor agonists, type 2 diabetes, pharmacokinetics, pharmacodynamics, glycemic control, exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, fasting hyperglycemia, postprandial hyperglycemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Is there a justification for classifying GLP-1 receptor agonists as basal and prandial? https://app.cochat.ai/papers/10.1186/s13098-017-0204-6
The paper
Miñambres, I., & Pérez, A. (2017). Is there a justification for classifying GLP-1 receptor agonists as basal and prandial? Diabetology & Metabolic Syndrome. https://doi.org/10.1186/s13098-017-0204-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.